Inhibition of Sp1 functions by its sequestration into PML nuclear bodies

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Li, June ^a   Zou, Wen Xin ^a   Chang, Kun Sang ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR SP1; NUCLEAR PROTEIN; PML PROTEIN, MOUSE; PROTEIN BINDING; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL NUCLEUS INCLUSION BODY; CELL NUCLEUS MATRIX; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RING FINGER MOTIF; SUMOYLATION; TRANSCRIPTION REGULATION; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; CHEMISTRY; GENETIC TRANSCRIPTION; HUMAN; METABOLISM; MOLECULAR GENETICS; PROMYELOCYTIC LEUKEMIA; PROTEIN MOTIF; PROTEIN TERTIARY STRUCTURE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; HUMANS; INTRANUCLEAR INCLUSION BODIES; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MOLECULAR SEQUENCE DATA; NUCLEAR MATRIX; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SP1 TRANSCRIPTION FACTOR; SUMOYLATION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84899634840     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094450     Document Type: Article

References (46)

1. Ascoli CA, Maul GG (1991) Identification of a novel nuclear domain. J. Cell Biol. 112: 785-795. (Pubitemid 21909627)
2. Dyck JA, Maul GG, Miller WH, Chen JD, Kakizuka A, et al. (1994) A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76:333-343. (Pubitemid 24046695)
3. Koken MH, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, et al. (1994) The t(15;17) translocation alters a nuclear body in a retinoic acidreversible fashion. EMBO J. 13:1073-1083. (Pubitemid 24074714)
4. Weis K, Rambaud S, Lavau C, Jansen J, Carvalho T, et al. (1994) Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76:345-356. (Pubitemid 24046696)
5. Hodges M, Tissot C, Howe K, Grimwade D, Freemont PS (1998) Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. Am. J. Hum. Genet 63:297-304. (Pubitemid 30418608)
6. Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, et al. (2006) Role of SUMOinteracting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 24:341-354.
7. Chen TH, Lin HK, Scaglioni PP, Yung TM, Pandolfi PP (2006) The mechanisms of PML-nuclear body formation. Mol Cell 24:331-339. (Pubitemid 44647906)
8. Buschbeck M, Uribesalgo I, Ledl A, Gutierrez A, Minucci S, et al. (2007) PML4 induces differentiation by Myc destabilization. Oncogene 26:3415-3422. (Pubitemid 46788887)
9. Gao C, Ho CC, Reineke E, Lam M, Cheng X, et al. (2008) Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation. Mol Cell Biol. 28:5658-5667.
10. Reineke EL, Lam M, Liu Q, Liu Y, Stanya KJ, et al. (2008) Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol Cell Biol. 28:997-1006. (Pubitemid 351160056)
11. Van Damme E, Laukens K, Dang TH, Van Ostade X (2010) A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. Int J Biol Sci. 6:51-67.
12. Seeler JS, Dejean A (1999) The PML nuclear bodies: actors or extras? Curr Opin Genet Dev. 9:362-367.
13. Regad T, Chelbi-Alix MK (2001) Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20:7274-7286. (Pubitemid 33105016)
14. Zhu J, Lallemand-Breitenbach V, de Thé H (2001) Pathways of retinoic acid-or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20:7257-7265. (Pubitemid 33107375)
15. Strudwick S, Borden KL (2002) Finding a role for PML in APL pathogenesis: a critical assessment of potential PML activities. Leukemia 16:1906-1917. (Pubitemid 35203433)
16. Boddy MN, Duprez E, Borden KL, Freemont PS (1997) Surface residue mutations of the PML RING finger domain alter the formation of nuclear matrix-associated PML bodies. J Cell Sci. 110:2197-2205. (Pubitemid 27448364)
17. Carvalho T, Seeler JS, Ohman K, Jordan P, Pettersson U, et al. (1995) Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrixassociated PML bodies. J Cell Biol. 131:45-56.
18. Chang KS, Fan YH, Andreeff M, Liu J, Mu ZM, et al. (1995) The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 85:3646-3653.
19. Tan NY, Khachigian LM (2009) Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol. 29:2483-2488.
20. Jutooru I, Chadalapaka G, Sreevalsan S, Lei P, Barhoumi R, et al. (2010) Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res. 316:2174-2188.
21. Liu S, Liu Z, Xie Z, Pang J, Yu J, et al. (2008) Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NFkappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 111:2364-2373. (Pubitemid 351451445)
22. Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R 3rd, et al. (2008) Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 68:5345-5354.
23. Pathi SS, Jutooru I, Chadalapaka G, Sreevalsan S, Anand S, et al. (2011) GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res. 9:195-202.
24. Hsu TI, Wang MC, Chen SY, Huang ST, Yeh YM, et al. (2012) Betulinic acid decreases Sp1 level via increasing the sumoylation of Sp1 to inhibit lung cancer growth. Mol Pharmacol. 82:1115-1128.
25. Vallian S, Chin KV, Chang KS (1998) The promyelocytic leukemia protein interacts with Sp1 and inhibits its transactivation of the epidermal growth factor receptor promoter. Mol. Cell. Biol. 18:7147-7156. (Pubitemid 28533034)
26. Spengler ML, Brattain MG (2006) Sumoylation inhibits cleavage of Sp1 Nterminal negative regulatory domain and inhibits Sp1-dependent transcription. J. Biol. Chem. 9:5567-5574. (Pubitemid 43847653)
27. Gong L, Yeh ET (2006) Characterization of a family of nucleolar SUMOspecific proteases with preference for SUMO-2 or SUMO-3. J. Biol. Chem. 281:15869-15877. (Pubitemid 43848478)
28. Quimby BB, Yong-Gonzalez V, Anan T, Strunnikov AV, Dasso M (2006) The promyelocytic leukemia protein stimulates SUMO conjugation in yeast. Oncogene 25: 2999-3005. (Pubitemid 43780464)
29. Tago K, Chiocca S, Sherr CJ (2005) Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc. Natl. Acad. Sci. U. S. A. 102:7689-7694. (Pubitemid 40741032)
30. Xu ZX, Zhao RX, Ding T, Tran TT, Zhang W, et al. (2004) Promyelocytic leukemia protein 4 induces apoptosis by inhibition of survivin expression. J. Biol. Chem. 279:1838-1844. (Pubitemid 38084451)
31. Wu WS, Xu ZX, Hittelman WN, Salomoni P, Pandolfi PP, et al. (2003) Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. J. Biol. Chem. 4:12294-12304. (Pubitemid 36800212)
32. Xu ZX, Zou WX, Lin P, Chang KS (2005) A role for PML3 in centrosome duplication and genome stability. Mol. Cell 17:721-732. (Pubitemid 40320921)
33. Hofmann TG, Will H (2003) Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ. 10:1290-1299. (Pubitemid 37536734)
34. Jensen K, Shiels C, Freemont PS (2001) PML protein isoforms and the RBCC/ TRIM motif. Oncogene 20:7223-7233. (Pubitemid 33105011)
35. Sternsdorf T, Jensen K, Reich B, Will H (1999) The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J. Biol. Chem. 274:12555-12566.
36. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, et al. (2000) Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19:6185-6195.
37. Georges A, Benayoun BA, Marongiu M, Dipietromaria A, L'Hôte D, et al. (2011) SUMOylation of the Forkhead transcription factor FOXL2 promotes its stabilization/activation through transient recruitment to PML bodies. PLoS One 6:25463.
38. Wimmer P, Schreiner S, Everett RD, Sirma H, Groitl P, et al. (2010) SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML. Oncogene 29:5511-5522.
39. Yamamoto H, Ihara M, Matsuura Y, Kikuchi A (2003) Sumoylation is involved in beta-catenin-dependent activation of Tcf-4 EMBO J. 22:2047-2059. (Pubitemid 36565530)
40. Goodson ML, Hong Y, Rogers R, Matunis MJ (2001) Sumo-1 modification regulates the DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor. J. Biol. Chem. 276:18513-18518.
41. Johnson ES. (2004) Protein modification by SUMO. Annu Rev Biochem. 73:355-382. (Pubitemid 39050373)
42. Seeler JS, Dejean A (2003) Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol. 4:690-699. (Pubitemid 37082184)
43. Gill G (2004) SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? Genes Dev. 18:2046-2059. (Pubitemid 39166622)
44. Pennati M, Folini M, Zaffaroni N (2007) Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28:1133-1139. (Pubitemid 47062670)
45. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS (2007) Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 19: 2013-2023. (Pubitemid 47353811)
46. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, et al. (2004) Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 96:269-279. (Pubitemid 38256272)